Anteris Technologies Global Corp. — Annual Report 2020

Feb 17, 2021

ASX ANNOUNCEMENT

18 February 2021

APPENDIX 4E AND FULL YEAR FINANCIAL REPORT

Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) releases its Appendix 4E – Full Year Financial Report and commentary for the period ended 31 December 2020.

FINANCIAL SUMMARY:

• Total revenue for year ended 31 December 2020 of $7.1M, largely generated from manufacturing of the CardioCel[®] and VascuCel[®] patches under the LeMaitre Vascular Inc. agreement.

• The Company recognised other income totalling $4.8M, which included $2.2M in licence income relating to contractual obligations from 4C Medical Technologies Inc. associated with the validation of the transfer of the sterilisation method for use with Anteris’ ADAPT[® ] tissue. Other income for 2020 also included $2.3M in government grants related to research and development activities.

• Selling, general and administrative expenses (SG&A) of $22.1M, significantly reduced compared to 2019 ($34.5M) reflecting lower employee costs and reduced travel and conference costs.

• Net loss after tax $15.3M, reflecting the primary focus on development of the DurAVR™ valve.

• Net cash outflow of $4.6M for the year. Year-end cash balance at 31 December 2020 was $4.4M.

• $1.1M raised via a private placement to sophisticated investors, a $1.2m short term facility secured against the Research & Development Refund for 2020 and subsequent to the year end secured a funding package of up to $20M with New York investment fund Mercer Street Global Opportunity Fund, LLC.

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT[®] tissue technology, paired with the unique 3D single-piece aortic valve design of DurAVR™, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Anteris Technologies Ltd

==> picture [95 x 51] intentionally omitted <==

Registered Office: Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066 Customer Service: T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Ms Kyahn Williamson WE Communications E: WE-AUAnterisTech@we-worldwide.com P: +61 401 018 828 www.anteristech.com Twitter: @AnterisTech Facebook: www.facebook.com/AnterisTech

==> picture [83 x 45] intentionally omitted <==

Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga